Biology of IDH mutant cholangiocarcinoma

Wu, Meng-Ju; Shi, Lei; Merritt, Joshua; Bardeesy, Nabeel

doi:10.1002/hep.32424

Cited by 35 publications

(17 citation statements)

References 161 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, IDH mutations are associated with the altered IL-1β responses in acute myeloid leukemia (AML) 98 . Mutations in IDH1 and IDH2 induce epigenetic and transcriptional reprogramming, and differentiation bias and promote the development of a number of malignancies 99 , 100 including but not limited to chondrosarcoma, AML 101 , 102 , cholangiocarcinoma 103 , prostate cancers 104 , angioimmunoblastic T-cell lymphomas 105 , myeloid neoplasia 106 . Thus, inhibition of IDH1 and IDH2 variants is being pursued as a medicinal chemistry target 107 .…”

Section: Mitochondrial Function In Cancer Cell Metabolismmentioning

confidence: 99%

An Overview: The Diversified Role of Mitochondria in Cancer Metabolism

Liu¹,

Sun²,

Guo³

et al. 2023

Int. J. Biol. Sci.

View full text Add to dashboard Cite

Mitochondria are intracellular organelles involved in energy production, cell metabolism and cell signaling. They are essential not only in the process of ATP synthesis, lipid metabolism and nucleic acid metabolism, but also in tumor development and metastasis. Mutations in mtDNA are commonly found in cancer cells to promote the rewiring of bioenergetics and biosynthesis, various metabolites especially oncometabolites in mitochondria regulate tumor metabolism and progression. And mutation of enzymes in the TCA cycle leads to the unusual accumulation of certain metabolites and oncometabolites. Mitochondria have been demonstrated as the target for cancer treatment. Cancer cells rely on two main energy resources: oxidative phosphorylation (OXPHOS) and glycolysis. By manipulating OXPHOS genes or adjusting the metabolites production in mitochondria, tumor growth can be restrained. For example, enhanced complex I activity increases NAD + /NADH to prevent metastasis and progression of cancers. In this review, we discussed mitochondrial function in cancer cell metabolism and specially explored the unique role of mitochondria in cancer stem cells and the tumor microenvironment. Targeting the OXPHOS pathway and mitochondria-related metabolism emerging as a potential therapeutic strategy for various cancers.

show abstract

Section: Mitochondrial Function In Cancer Cell Metabolismmentioning

confidence: 99%

An Overview: The Diversified Role of Mitochondria in Cancer Metabolism

Liu¹,

Sun²,

Guo³

et al. 2023

Int. J. Biol. Sci.

View full text Add to dashboard Cite

show abstract

“…The Wnt/β-catenin pathway Compared to HCC, a lower proportion of CC patients display mutations of genes involved in the Wnt-βcatenin cascade, which, potentially, could be a target for treating and reversing multi-drug resistance [164,181,182] .…”

Section: Pathways Related To Development the Notch Pathwaymentioning

confidence: 99%

Metabolic primary liver cancer in adults: risk factors and pathogenic mechanisms

Lugari¹,

Baldelli²,

Lonardo³

2023

Metab Target Organ Damage

View full text Add to dashboard Cite

Primary liver cancer (PLC) is a heterogeneous group of disorders arising with the background of chronic liver disease (CLD) owing to varying etiologies. PLC carries a high lethality rate and a substantial epidemiological, clinical, and financial burden, which is projected to escalate. The two most common PLC histotypes in adults are hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC); the latter is sub-classified as either intrahepatic CC or extrahepatic CC. Over recent decades, there has been a decline of viral CLD accompanied by an increase in dysmetabolic CLD, resulting in PLC becoming relatively more common in Western countries. Metabolic co-morbidities are risk factors and co-factors for HCC and (increasingly) CC. Complex immunological, cellular, pro-inflammatory, molecular, and genetic processes in the systemic dysmetabolic milieu increase PLC risk. Improved understanding of these mechanisms requires close surveillance and early diagnosis of at-risk patients while paving the way for personalized medicine, chemoprevention, and innovative management of metabolic PLC.

show abstract

“…Wu hopes that this work will inform strategies to improve the clinical efficacy of ivosidenib in patients with mutant IDH1 cancers. 17,18…”

Section: Importance Of T Cells In Targeting Midh1 In Cholangiocarcinomamentioning

confidence: 99%

“…Combining ivosidenib with anti‐CTLA‐4 antibody (an immune checkpoint blocker) led to long‐term tumor shrinkage that persisted even after treatment ended (Figure 1). Wu hopes that this work will inform strategies to improve the clinical efficacy of ivosidenib in patients with mutant IDH1 cancers 17,18 …”

Section: Metabolic Regulation Of the Anticancer Immune Responsementioning

confidence: 99%

Immunometabolism at the crossroads of obesity and cancer—a Keystone Symposia report

Cable¹,

Rathmell

Pearce

et al. 2023

Annals of the New York Academy of Sciences

Self Cite

View full text Add to dashboard Cite

Immunometabolism considers the relationship between metabolism and immunity. Typically, researchers focus on either the metabolic pathways within immune cells that affect their function or the impact of immune cells on systemic metabolism. A more holistic approach that considers both these viewpoints is needed. On September 5–8, 2022, experts in the field of immunometabolism met for the Keystone symposium “Immunometabolism at the Crossroads of Obesity and Cancer” to present recent research across the field of immunometabolism, with the setting of obesity and cancer as an ideal example of the complex interplay between metabolism, immunity, and cancer. Speakers highlighted new insights on the metabolic links between tumor cells and immune cells, with a focus on leveraging unique metabolic vulnerabilities of different cell types in the tumor microenvironment as therapeutic targets and demonstrated the effects of diet, the microbiome, and obesity on immune system function and cancer pathogenesis and therapy. Finally, speakers presented new technologies to interrogate the immune system and uncover novel metabolic pathways important for immunity.

show abstract

Biology of IDH mutant cholangiocarcinoma

Cited by 35 publications

References 161 publications

An Overview: The Diversified Role of Mitochondria in Cancer Metabolism

An Overview: The Diversified Role of Mitochondria in Cancer Metabolism

Metabolic primary liver cancer in adults: risk factors and pathogenic mechanisms

Immunometabolism at the crossroads of obesity and cancer—a Keystone Symposia report

Contact Info

Product

Resources

About